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Abstract
Antiretroviral therapy is not curative. Given the challenges in providing life-long therapy to a 
global population of over 35 million people living with HIV, there is intense interest in developing 
a cure for HIV infection. The International AIDS Society convened a group of international 
experts to develop a scientific strategy for research towards an HIV cure. This Perspective 
summarizes the group's strategy.
INTRODUCTION
The HIV/AIDS pandemic represents the most important global health challenge in modern 
history. Fortunately, when used optimally, combination antiretroviral therapy (ART) can 
effectively control HIV replication, prevent the development of AIDS, prolong life and 
reduce transmission risk. Despite this unquestioned success, there are limitations with 
current treatment strategies. The operational and logistical challenges in delivering life-long 
treatment are daunting and the economic costs of providing ART to over 35 million people 
currently living with HIV may be unsustainable1. Life-long adherence treatment is 
challenging for many. Antiretroviral drug resistance remains a problem, particularly in those 
individuals who are unable to fully adhere to treatment. Drug toxicities and the persistence 
of immune dysfunction during ART have significant health consequences. These factors 
highlight the urgency of identifying an effective means to control the virus in the absence of 
ART, or a cure (Text Box 1). The search for a curative strategy for HIV is now a key priority 
for the HIV community2 and encouraging results have already been reported (Figure 1 and 
Text 2).
The International AIDS Society (IAS) established the “Towards an HIV Cure” initiative in 
2010. A major outcome of this initiative was the development in 2012 of a long-term 
scientific strategy by a large, multi-disciplinary group of scientists3. Given the evolving 
nature of HIV cure research (Text Box 2), the initiative expanded its scope by adding new 
members with unique expertise relevant to the emerging agenda, broadening the strategy 
beyond biomedical research to include social and behavioural sciences (Text Box 3). This 
second edition of the Global Scientific Strategy: Towards an HIV Cure 2016 describes the 
critical knowledge gaps and research questions in the field (Table).
MOLECULAR BIOLOGY OF HIV LATENCY
Background
A major barrier to curing HIV is latency, which is defined as the persistence of integrated 
viral DNA that is replication competent but transcriptionally silent. HIV persists primarily as 
a latent genome in long-lived memory CD4+ T cells and to a lesser degree in naive CD4+ T 
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cells. Whether latency occurs in myeloid cells remains controversial. Multiple cellular 
mechanisms have been defined that contribute to the establishment and maintenance of 
latency (Figure 2). A repressive chromatin environment is actively maintained at the HIV 
long terminal repeat (LTR) by the activity of histone deacetylases and other regulatory 
proteins and by the absence of host factors needed to support viral transcription, including 
nuclear factor kappa B (NF-Kb) and positive transcription elongation factor b (PTEF-b)4–6. 
Transcriptional interference by host promoter activities also prevents successful HIV 
proviral transcription7. These multiple levels of transcriptional control confer an apparent 
stochastic nature to HIV proviral DNA expression, whereby even in the face of multiple 
activating signals, latency cannot be instantaneously disrupted in all proviral genomes8.
The contribution of residual low-level (or “cryptic”) virus replication and spread during ART 
to HIV persistence is unresolved. Two controlled studies of ART intensification with the 
integrase inhibitor, raltegravir, found evidence of persistent cycles of virus replication in a 
subset of participants9,10. A study of HIV sequence evolution within lymph node tissue 
found evidence of viral evolution within the first six 6 months of initiating ART, consistent 
with low-level replication11,12, but other studies of long-term ART failed to find any 
evidence of evolution13, even in tissues14.
The current most-studied approach for eliminating latently infected T cells is based on the 
hypothesis that HIV latency can be reversed, leading to the clearance of these cells through 
virus or immune mediated cytolysis (“shock and kill”). Although the administration of 
LRAs, including histone deacetylase inhibitors (HDACi) and disulfiram to HIV-infected 
individuals on ART have demonstrated an increase in both cell associated and plasma HIV 
RNA, these interventions had no apparent effect on the frequency of latently infected 
cells15–18. It is unknown whether current approaches have failed because they are 
insufficiently potent or because cells induced to produce virus are not cleared19.
Understanding blocks in HIV transcription and virus production in latently infected resting 
cells
Basic research on the cellular mechanisms that constitute the rate-limiting steps controlling 
gene expression in resting CD4+ T-cells may be informative. Indeed, a better understanding 
of factors that allow or restrict transcriptional initiation and RNA processing at the HIV 
LTR, and how to manipulate these factors therapeutically is needed (Figure 2).
HIV RNA transcription is not the only event that is required to effectively disrupt latent 
infection. HIV mRNA export, splicing and translation, viral antigen expression, and/or 
processing and presentation have been relatively under-studied, especially within resting 
memory CD4+ T-cell populations. A full understanding of the steps and processes that allow 
the rare latently infected cell to be revealed to the immune system, or to be targeted, is still 
lacking.
Development of in vitro models of HIV latency
The field currently lacks validated systems with which to test and compare different 
“latency-reversing agents” (LRAs)20. The development of in vitro cellular models based on 
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resting CD4+ T-cells is critically needed. These models will need to reiterate the biology 
critical for the establishment and maintenance of latency.
Development of more selective and effective LRAs
While it is clear that LRAs can stimulate the production and release of virions from a small 
subset of infected cells in vitro, more potent LRAs are needed. This will likely require the 
redistribution or upregulation of several key cellular factors with combination therapies21. 
Identifying such combinations with current in vitro systems will be challenging as these 
systems fail to capture the complex in vivo signalling networks that maintain memory cells 
in a resting state (and hence maintain latent infection). One new approach under study may 
function indirectly by activating antigen-presenting cells to signal and activate memory cells 
(e.g., toll-like receptor agonists). Current systems are also unable to study LRA activity over 
prolonged periods, which will likely be needed given the stochastic nature of latency 
reversal, and highlight the role of animal models in this research.
All LRAs target host cellular pathways and hence might have untoward effects on multiple 
other host genes22. LRAs that broadly activate all T cells will likely reverse latency, but the 
inflammatory consequences will almost certainly prove risky23. LRAs that alter the 
epigenetic environment that silences DNA transcription could increase the risk of malignant 
transformation; indeed, the first generation of LRAs studied in the clinic (vorinostat and 
panobinostat) had mutagenic potential in common screening assays. Given non-specific 
effects on the activation status of memory cells, some LRAs have the potential to stimulate 
cell proliferation, which could lead to expansion of an infected cell population24,25. Immune 
modifying drugs that mitigate this response may need to be developed along with LRAs. 
Finally, these approaches will have to be carefully vetted for their potential to dampen the 
very immune responses needed for viral clearance26.
Strategies to permanently silence the HIV provirus
An alternative approach that represents a significant departure from the “shock and kill” 
paradigm is to fully and irreversibly suppress HIV transcription, leading to permanent 
silencing and the lack of virus production when ART is discontinued. This strategy will 
likely require a greater degree of specificity with respect to targeting the HIV LTR27,28. We 
lack an understanding of the molecular mechanisms involved in pharmacologically-mediated 
“deep” latency, and the durability of this state.
Defining the role of HIV replication as a cause of persistence
The role of ongoing HIV replication in maintaining HIV persistence remains controversial. 
HIV may continue to spread despite ART as a consequence of insufficient drug potency, 
pharmacologic barriers that prevent distribution of treatment to all tissue reservoirs and/or 
lack of effective immunity, particularly in potential immune-privileged sanctuaries. Assays 
that can assess new infection events rather than simply the production of virions will need to 
be developed; these assays will presumably need to be validated using lymphoid tissues. 
Novel strategies that overcome potential mechanisms for persistent replication (e.g., more 
potent ART, enhanced T cell immunity) will need to be studied in animal models and 
eventually people to determine if replication persists and if it can be inhibited.
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THE IMMUNOLOGY OF HIV PERSISTENCE
Background
Untreated HIV causes irreversible harm to the immune system. Effective ART reverses many 
of these abnormalities, but a state of persistent inflammation and immune dysfunction 
typically persists. This immune state during ART is characterized by chronic low level 
inflammation within the adaptive and innate immune systems, elevated immunoregulatory 
responses, and CD4+ and CD8+ T cell dysfunction. It is expected that this compromised 
immune state contributes to HIV persistence on ART and that efforts to control HIV in the 
absence of ART may require interventions that reverse some or all of these immunologic 
abnormalities29.
Characterizing and quantifying the total body burden of replication-competent HIV is 
challenging as most of the virus resides in difficult-to-access lymphoid issues. In blood and 
tissues, HIV primarily persists in either latently or productively infected memory CD4+ T 
cells30–32. Over time, the virus may become enriched in memory cells with self-renewing 
stem-cell like capacity33. T follicular helper (Tfh) may also be highly enriched for 
replication-competent virus, perhaps because they largely reside in B cell follicles, which are 
relatively inaccessible to HIV-specific CD8+ T cells34,35. Although macrophages are 
productively infected during untreated HIV infection, it has proven difficult to demonstrate 
conclusively that replication-competent HIV persists indefinitely in these cells during ART36 
or that HIV persists in those tissues that are rich in macrophages, particularly the central 
nervous system37,38.
It is generally accepted that the biology of CD4+ T cell memory determines the fate of 
latently infected cells. Major knowledge gaps exist in this area. The life span of these cells in 
vivo is unknown. Clonal expansion of HIV in memory CD4+ T cells is apparently common, 
perhaps because the site where HIV integrates enhances cell proliferative or survival 
capacity14,39–42. The relative contributions of cytokine-mediated T cell turnover (T cell 
homeostasis) versus antigen-mediated T cell activation on the persistence of the replication-
competent reservoir is unknown, but massive and sustained clonal expansion of cells 
containing an intact provirus capable of sustaining infectious viremia has been reported42.
Defining the distribution of HIV during ART
We need to better define and quantitate the anatomical and cellular sites of HIV persistence 
on ART, and assess their evolution over time. For accessible tissue sites (e.g., lymph node 
and gut), the spatial distribution of the replication-competent virus should be defined and the 
degree that active replication persists within putative “sanctuaries” (e.g., the B cell follicle or 
variable sites of antiretroviral penetration) determined12,35. For tissue sites that are less 
accessible (e.g., spleen, brain, genital tract, and thymus), tissue banks should be accessed as 
these contain samples both from biopsies and autopsies of HIV-infected people who died 
while on ART. It is expected that further validation of non-human primate models will 
complement these human studies.
A number of questions persist regarding the memory CD4+ T cell populations that harbour 
HIV during ART. Is HIV enriched in cells with certain antigen-specificity during ART? Can 
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replication-competent HIV be readily found in all CD4+ T cell populations, including T 
regulatory cells, Th1, Th2, Th17, and Tfh cells? Does the distribution of virus across these 
populations change over time? What is the nature of the tissue-resident CD4+ T cells that 
harbour latent HIV and cannot be readily sampled in humans? Does signalling between 
antigen-presenting cells (e.g., dendritic cells, macrophages) and neighbouring infected cells 
in lymphoid tissues contribute to latency43?
An emphasis should be placed on exploring how human variability (e.g., host genetics, age, 
gender, co-morbidities, co-infections, HIV disease progression state, and the microbiome) 
affects HIV persistence on ART. Since the majority of those infected with HIV are 
chronically co-infected with other pathogens such as malaria, Mycobacterium tuberculosis, 
hepatitis B and C virus and helminthic worms, the impact of such co-infections on the 
persistence of HIV should also be studied. Also, as the epidemic matures, more people will 
have been on suppressive ART for up to two decades. The long-term (decades) stability of 
the reservoir in terms of size, distribution, response to activation and replication-competence 
should be defined.
Defining the biology of the reservoir
How CD4+ T cell memory is established and maintained in humans has not been fully 
characterized. These efforts will likely involve transcriptomic and proteomic analysis of 
infected cells as well as analysis of the transcriptional state of the virus. The impact of 
anatomical site, microenvironment, cellular metabolism, and microbiome on T cell 
dynamics should be defined.
Enhancing capacity of the immune system to clear or control HIV
Most cure strategies will require active elimination of infected cells or control of HIV 
persistence by T cells, antibodies, NK cells and/or macrophages. With regard to enhancing T 
cell function, a number of approaches should be pursued. T cell vaccines that are able to 
enhance HIV-specific immunity remain a priority. There is specific interest in approaches 
that stimulate responses against novel, non-dominant epitopes, given that cytotoxic T 
lymphocyte (CTL) escape to standard (canonical) epitopes likely exist in the majority of 
individuals and that most vaccines appear to stimulate pre-existing memory responses44. A 
potent cytomegalovirus (CMV) vector reengineered to stimulate sustained responses to 
novel, non-immunodominant epitopes has shown promise in nonhuman primate 
models45–47.
Broadly neutralizing antibodies (bNabs) may also play a role48–52. The degree to which such 
antibodies might target latently infected cells that go on to express viral antigens 
spontaneously or following induction by a LRA, or are able to overcome the sequence 
diversity which emerges in chronic infection needs to be defined. The optimal effector 
pathway (e.g., natural killer (NK) cells, macrophages, complement) for clearing infected 
cells is unknown53. Therapies that target effector cells that home to lymphoid tissue, 
including chemokine blockade and/or disruption of B-cell follicles, should also be pursued. 
Bi-specific antibodies that enhance virus production and simultaneously recognize and 
eliminate virus-expressing cells have shown promise in pre-clinical models and should be 
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advanced into the clinic, recognizing that potentially harmful off-target effects may 
occur54,55.
Targeting T cell homeostasis and T cell dysfunction
Therapies aimed at reversing chronic inflammation could contribute to cure or remission by 
(1) altering the chronically dysfunctional immunoregulatory environment with an aim at 
enhancing T cell function, (2) reducing T cell proliferation (homeostatic and antigen-driven) 
and (3) reducing virion production and the generation of new target cells, thereby reducing 
virus spread. Proof-of-concept for these approaches was recently demonstrated in non-
human primates56. Potentially targetable pathways that could be informative if blocked or 
enhanced include immune checkpoints (PD-1, CLTA-4, TIGIT, others), IDO, IL-18, mTOR, 
JAK/STAT, IL-10, and TGF-beta, among others.
Many of these approaches have significant risks, which makes studies in generally healthy 
HIV-infected adults on ART challenging from an ethical perspective. More interactions 
between HIV specialists and other disciplines working with these approaches are urgently 
needed. There may be particular synergies between HIV and those working in oncology, 
autoimmune diseases, and transplantation. Indeed, careful studies of HIV-infected adults 
undergoing transplantation have revealed novel insights regarding HIV persistence on ART 
and the potential role of immune-modifying therapies57,58. Careful studies of HIV-infected 
adults with cancer receiving immune checkpoint blockers and other emerging 
immunotherapies should prove to be particularly informative and may lead to identification 
of novel curative strategies for HIV infection59.
Developing and maintaining well-characterized cohorts
Studies of those who control HIV naturally (“elite controllers”) have provided the strongest 
evidence to date that HIV-specific CD8+ T cell immunity can contribute to virus control60. 
More recently, a group of individuals who might have been destined for poorly controlled 
HIV was possibly turned into long-term controllers by the early introduction of ART that 
was subsequently discontinued61,62. The development of larger cohorts of these “post-
treatment controllers” will be needed to confirm these provocative findings. Other cohorts 
that will likely prove valuable include those of individuals undergoing solid organ 
transplantation58 or of individuals receiving immunotherapy and other treatments for the 
management of cancer and other chronic disease59.
MODELS FOR HIV CURE OR SUSTAINABLE REMISSION
Background
Animal models involving experimental AIDS virus infection of non-human primates and 
humanized mice provide numerous important experimental advantages, including the ability 
to control experimental variability, definition of the identity, size, timing, and route of the 
virus inoculum, and flexibility of experimental and therapeutic interventions. The ability to 
perform extensive tissue sampling in animal models, including elective necropsy, is a key 
advantage as the vast majority of virus that persists on ART resides in tissues that are 
difficult to impossible to sample in a clinical setting. These models are important 
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contributors to the overall research effort aimed at achieving HIV remission. Studies 
utilizing animal models have informed the field about how quickly latency is established, the 
anatomic and cellular components of the reservoirs, and the responses to novel 
interventions35,63,64. ART regimens have recently been developed that can achieve and 
maintain clinically relevant levels of viral suppression in nonhuman primate models, and 
encouragingly with regard to the potential predictive value of such studies, results in 
nonhuman primate studies of latency reactivating agents have paralleled results from clinical 
studies of the same agents65.
Humanized mouse models have also been used for studies in this area, but limitations on 
sampling from individual animals, the relatively short duration of feasible studies (weeks) 
and graft vs host disease in many models restrict their utility to addressing only certain 
questions64,66. However, such models permit the rapid evaluation of selected strategies in the 
context of HIV infection of human immune cells.
Development of models
Due to the high bar to clinical testing of unproven and potentially hazardous interventions in 
a population doing well with standard of care ART, animal models provide an important 
pathway for the evaluation of novel strategies to achieve cure or sustained off ART 
remission of HIV infection, serving as a key step for in vivo proof of concept study and 
safety testing. Key research questions in this setting include further efforts to establish 
whether these models recapitulate known and newly discovered features of HIV persistence 
in humans on ART, including cellular and anatomic sites of residual virus, cellular and 
molecular factors influencing latency, the nature of immune dysregulation, and responses of 
the infected hosts to experimental interventions. Results to date are encouraging, although 
some important aspects, such as potential differences in the biology of HIV persistence in 
HIV-infected humans that have been on ART for decades, can be effectively modelled in 
studies of shorter duration. Iterative studies in which cycles of preclinical experiments in 
animal models are informed by emerging clinical data offer great promise to provide insights 
into the most relevant and effective approaches.
Identity viable combination regimens
It is unlikely that any single intervention will result in a durable remission or cure. Most 
long-term strategies now being pursued involve combinations of various approaches. 
Examples include combinations of two or more latency reversing agents with therapies 
aimed to enhance clearance of virus-producing cells (“shock and kill”) or combinations of 
therapeutic vaccines with adjuvants and/or immune modifying agents (e.g., immune 
checkpoint inhibitors). Identifying, developing and optimizing such combinations will be 
challenging in humans, given that many combinations will need to be tested, and that 
characterizing the safety and pharmacology of individual interventions will likely need to be 
completed before such combinations can even be considered. Once animal models are fully 
optimized, well-resourced, iteratively designed and adequately powered studies of single and 
combination approaches should be performed, with the most promising combinations 
advanced into humans.
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HIV REMISSION IN THE PEDIATRIC POPULATION
Background
Worldwide there are almost 4 million children living with HIV and 250,000 are infected 
every year61. Children face a prospect of life-long ART and the added challenges associated 
with ART through childhood and adolescence (e.g. limited appropriate drug formulations, 
poor adherence). As such, HIV remission represents an especially desirable goal for the 
pediatric population.
Perinatal HIV-infection offers a unique opportunity to assess prompt control of HIV 
replication because of the known timing of HIV exposure through maternal infection. Other 
factors that may potentially further reduce the frequency of latently infected cells include 
immune tolerance in infancy, lower immune activation compared to adults, and the slower 
pace of T cell memory development67–69.
Characterize mechanisms for persistence
The major knowledge gaps for perinatal HIV infection are in understanding the mechanisms 
of latency in infants and children. The dynamics of HIV persistence in children are probably 
different than those in adults, owing to a number of factors such as the types and numbers of 
target cells, efficiency in clearing HIV-infected cells, and pharmacokinetics of ART in blood 
and tissues. Little is known about the development of the newborn and infant innate and 
adaptive immune system, and about the role of immune activation, homeostasis, 
inflammation, and viral and host factors in the establishment and maintenance of HIV 
latency70. Early ART can preserve normal development of B and T cells, as demonstrated by 
the ability to mount immune responses against childhood vaccines. However, there is limited 
understanding about the development of HIV-specific B and T cell immunity including 
neutralizing and non-neutralizing antibodies, and effector and polyfunctional T cell 
responses. Development of techniques for virologic and immunologic characterization that 
require small blood volumes is critical to advancing paediatric cure research. Infant animal 
models could be used to fill gaps and limitations in pediatric HIV pathogenesis and 
mechanisms of interventions.
CELL AND GENE THERAPY
Background
There is growing interest in the potential of gene and cell therapies to treat HIV infection 
(Figure 3). This has been driven in part by recent technological advances and successes in 
other disease areas, especially inherited immune deficiencies and cancer, and the successful 
outcome for Timothy Brown71. This individual received a hematopoietic stem cell (HSC) 
transplantation as part of treatment for acute myeloid leukemia, from a donor who was 
homozygous for the CCR5Δ32 deletion and therefore resistant to HIV infection. Mimicking 
this approach, most gene therapies to date for HIV have been based on engineering a 
patient’s own (autologous) cells to confer HIV-resistance, either by removing CCR572 or 
introducing genes that encode anti-HIV proteins73,74.
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Gene therapies are also being considered as a way to directly remove HIV-infected cells on 
ART, although daunting technical barriers exist. Other approaches seek to target integrated 
HIV genomes for inactivation using engineered nucleases such as zinc finger nucleases 
(ZFNs), TAL effector nucleases (TALENs) or CRISPR/Cas975 although directing such 
treatments to latently infected cells in vivo poses substantial challenges, including the 
potential off-target mutations. More practically, immune cells could be modified to 
recognize and destroy HIV-infected cells that express HIV antigens76 in the same way that 
engineered T-cell receptors or chimeric antigen receptor (CAR) T cells have proven 
successful against certain cancers77,78. Finally, cells could be turned into factories for the 
long-term production of anti-HIV molecules, such as broadly neutralizing antibodies79 or 
CD4/CCR5 mimetics80.
Since fully myeloablative conditioning will not be acceptable in non-cancer settings, the 
percentage of gene-modified cells immediately post-transplant will represent a minority of 
the cells in the body. Although it is assumed that there could be some selection for gene 
modified HIV-resistant cells as the virus depletes those that remain gene unmodified and 
hence HIV-susceptible, this may not be effective if ART is maintained and there is little/no 
replicating virus in the individual. Such selection could be temporarily induced with a 
treatment interruption, although how long a period of uncontrolled virus replication would 
be required to select for a sufficient number of gene modified cells is unknown, and there 
will be limited support for studies that require prolonged periods of viremia.
Explore the potential of engineered T cells to eliminate HIV-infected cells
The field of T cell engineering is rapidly moving, with great successes in the area of 
immunotherapies for cancer. In a similar approach, it is possible that engineering T cells to 
express modified TCRs, or CARs recognizing HIV antigens, could provide control of HIV 
or eliminate infected cells. Other immune effector cells are also being developed as 
candidates for these methods81.
Develop an HIV-resistant T cell population
There are a number of gene modifications that might render a T cell resistant to HIV infect. 
Achieving a life-long remission will likely require protecting all possible target cells, 
including CD4+ T cells and perhaps monocyte/macrophages. The ideal population to target 
are hematopoietic stem cells (HSCs) as they are long-lived precursors for multiple cell types, 
but these cells are rare and technically challenging to isolate, gene-modify and engraft. As 
reengineered stem cells have the potential for malignant transformation, the use of “kill 
switches” (genes which can be activated to cause cell death) will likely need to be 
considered.
Develop methods to deliver targeted nucleases to latently infected cells
Targeted nucleases such as ZFNs and CRISPR/Cas9 can disrupt HIV proviral DNA in cell 
culture models, but their application in HIV-infected individuals will require enhanced 
methods of delivery. This includes the challenge of delivery to the rare, latently infected 
cells that may not express HIV antigens. Achieving in vivo delivery is a challenge for the 
field of gene therapy in general.
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Apply methods to boost immune responses in combination with cell and gene therapies
It is uncertain if genetically modified HSC or T cells, even if they are resistant to HIV 
infection, could mediate eradication of other infected cells. Thus some additional 
mechanisms will likely be required to control or eliminate persistent HIV, while the gene-
modified HIV-resistant cells protect against re-infection. Cell and gene therapies could 
therefore be combined with other treatments that boost HIV-specific immune responses, 
including novel therapeutic vaccine strategies, drugs modulating T cell responses such as 
PD-1 inhibitors, and LRAs. There are already some indications that engineered HSC- 
derived CD4 T cells or peripheral T cells can boost the endogenous immune system to 
control HIV74,82 but this needs to be understood better.
Development of less toxic immunosuppressive conditioning regimens
While the efficiency of rendering T cells or HSCs resistant ex vivo has improved 
substantially over the past years, there is still an enormous problem in getting these cells to 
engraft without the use of toxic conditioning regimens. Although chemoablation increases 
the efficiency of engraftment of gene-modified HSCs and T cells, there are concerns about 
its toxicity. One mitigating approach is to do such studies first in HIV-infected individuals 
with cancer, but this patient population is small and getting smaller. More investigation is 
needed into the long-term effects of such treatments since the risks of ablation in the 
autologous gene therapy setting are unknown. Thus, novel less toxic regimens need to be 
developed. These include safer (non-mutagenic) methods of conditioning and the possibility 
of positive selection for engineered cells in vivo, post-transplantation83.
NOVEL BIOMARKERS TO ANALYSE/QUANTIFY HIV RESERVOIRS
Background
The quantitative viral outgrowth assay (QVOA) has long been considered the gold-standard 
for measuring the size of the replication-competent reservoir84–86. The assay is labour 
intensive, expensive and requires large numbers of cells. Recent advances in measuring 
inducible virus have included a similar limiting dilution format but measuring production of 
cell associated RNA or release of viral RNA in supernatant87,88 and amplification of latent 
infectious virus using a humanized mouse model – the murine viral outgrowth assay 
(MVOA)89.
HIV-infected cells can also be quantified using PCR based assays. Total or integrated HIV 
DNA are both high throughput assays that are more easily standardised; however, they over 
estimate the number of latently infected cells because most proviruses that persist during 
ART have lethal mutations or deletions8,90. Quantification of low-level plasma viremia by 
single copy assay is useful in studies of latency reversal but its relationship with the 
frequency of latently infected cells is unclear (Figure 4)90.
It is possible that measuring the immune response to HIV could be a more sensitive strategy 
to detect residual virus than measuring the virus itself. The avidity and concentration of HIV 
antibodies appears to change with declining numbers of latently infected cells91 and markers 
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of T cell activation and proliferation have been shown to correlate with the number of 
latently infected cells in multiple studies29.
No biomarker has been identified that can accurately and consistently predict time to viral 
rebound following ART discontinuation or the duration of ART-free remission, although 
progress is being made92,93. In the absence of predictable biomarkers of virologic rebound, 
assessment of HIV remission requires interruption of ART.
Define the performance characteristics of existing and evolving biomarkers
The performance characteristics of putative biomarker assays need to be much better 
characterized through unbiased assessment of sensitivity, specificity, precision and accuracy 
through testing of blinded panels of clinical samples that are prepared and distributed by a 
central organization. Impartial, centralized distribution of test panels and data analysis are 
critical components of the research infrastructure needed to accurately determine biomarker 
assay performance. These efforts should include both blood-based and tissue-based 
biomarkers.
Develop highly sensitive biomarkers of HIV persistence
Biomarkers in blood may be too insensitive to adequately represent the extent of HIV 
persistence in tissue35. Indeed, in the previous case reports of prolonged remission following 
HSC transplantation in Boston94 and very early ART administration to a child born to an 
untreated HIV-infected mother in Mississippi95 provide evidence that blood sampling alone, 
perhaps because there is a limit to how much blood can be collected, will be inadequate as a 
measure of HIV persistence. Less cumbersome and more scalable means of sampling tissue 
reservoirs need to be achieved as a potential means of increasing the sensitivity of 
biomarkers of HIV persistence. Advances in whole body imaging technologies such as 
immune-PET scanning96 and stereotactic guided tissue sampling hold promise but reduction 
of risk and simplification of the sampling process to that equivalent to phlebotomy are 
formidable challenges. Animal models, such as humanized mice and the MVOA can 
enhance the lower limit of sensitivity to detect infectious HIV allowing for the use of large 
numbers of human cells that exceed what is currently possible in vitro, although these 
models will be limited by amount of cells which can be infused and by costs.
Identify specific markers of an infected cell
There is a compelling need to identify phenotypic markers for latently infected cells in vivo. 
It has been argued that HIV is enriched in cells that express markers of T cell activation and 
function, including HLA-DR, CCR5, CCR6, CXCR3 and PD-130,97–99 although it is likely 
that only a fraction of cells expressing such markers harbour latent HIV. Whether persistent 
virus in activated cells differs from resting cells remains unclear. The identification of 
markers for the infected population could allow more targeted therapies.
Develop methods for detection of replication-competent proviruses
These methods may involve nucleic acid detection of signature proviral sequences that are 
present only in intact proviruses and not in defective ones; high throughput, full-length 
single genome sequencing to identify intact proviruses; or simplified virus outgrowth assays 
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that induce the complete reactivation of latent but intact proviruses, potentially using 
additional stimuli other than activation of the T-cell receptor100. Recent innovations in high-
throughput analyses of single cells should be applied with the goal of quantifying rare cells 
with inducible, intact proviruses.
Develop non-virologic biomarkers that quantify the total-body reservoir
Potential biomarkers of this type include the levels of antibody to specific HIV proteins, the 
affinity of antibodies for such proteins, or the frequency of B-cells responsive to specific 
HIV-1 antigens. Similarly, assays to assess the frequency of CD4+ or CD8+T-cells that are 
responsive to specific HIV-1 antigens should be sought as markers of HIV-1 persistence. 
Host transcriptional or metabolic signatures of continued innate or adaptive immune 
response to HIV-1 nucleic acids or proteins may also prove to be sensitive markers of HIV-1 
persistence.
Validate biomarkers for use in studies of HIV cure/remission
Any putative biomarker needs to be validated as a predictor of the duration of ART-free 
remission. A major repository of biologic samples of various types (blood, body fluids and 
tissues) and a robust clinical database of individuals who suspend ART in a controlled 
manner, are essential for validation of candidate biomarkers.
Characterize and validate biomarkers for all HIV subtypes
An infrastructure to support biomarker development on a global scale will be needed to 
ensure that assays are optimised to detect common circulating HIV clades, in addition to 
subtype B.
SOCIAL SCIENCES AND HEALTH SYSTEMS RESEARCH
Background
Given the complexity of cure science outlined in the preceding sections, research on science 
translation and public engagement is critical. Social science research on HIV cure has the 
potential to guide meaningful community engagement, ensure ethical conduct of research, 
mitigate the risks of behavioural disinhibition and therapeutic misconception, enhance 
patient-physician communication, engage global key populations, ensure economic viability, 
and reduce pervasive HIV and sexual stigma. Health systems research can facilitate policy-
relevant research synergies, assist with health systems preparedness, spur public-private 
collaboration, and inform effective community engagement strategies.
Identify HIV-infected individuals’ perceptions
The voices of HIV-infected individuals always have been central to the HIV response, and 
this must extend to cure research101. For many individuals with HIV infection, their 
serostatus has been the basis for making a number of decisions that influence health (e.g., 
serosorting and other sexual behaviours) and wellbeing (e.g., participation in community 
groups and advocacy). How they understand the meaning of HIV cure is important, because 
these beliefs may influence participation in clinical trials, trust in HIV service delivery 
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systems, engagement in care and treatment, serostatus disclosure, and ongoing risk and 
protective behaviours.
The personal, behavioural, ethical and social implications of participating in HIV cure 
clinical research warrant greater attention in the context of clinical research. Examples of 
this type of research include the following: research about how to effectively communicate 
the science, benefits and risks of HIV cure trials as part of informed consent102,103; 
qualitative research among HIV-infected trial participants and their partners about how 
participation in cure studies affect the participant’s HIV identity, sexual behaviours, and 
social relationships; and research on how HIV-infected individuals understand (or 
misunderstand) ongoing HIV cure research104,105.
Measuring and increasing stakeholder engagement
There are multiple stakeholders in cure research, including HIV-infected individuals, key 
affected populations, health professionals, scientists, funding agencies, international 
agencies, public health and regulatory authorities, pharmaceutical industries, and civil 
society organizations. The history of HIV intervention research shows how early stakeholder 
engagement along multiple levels can help increase the likelihood of success and mitigate 
failure106. However, there are many key research areas that require further investigation, 
including the following: better and more standardized tools for measuring stakeholder 
engagement and its downstream effects (e.g., changes in retention rates and recruitment pace 
in cure research projects); optimal timing and substance of HIV community and non-
community stakeholder engagement, including investigation of the role of community 
advisory boards in representing the community research interests; ensuring affordability of 
community engagement strategies, especially in resource-constrained contexts.
Clinical trial equity and inclusiveness
In order to ensure an equitable distribution of cure strategies, it is essential to incorporate a 
diverse group of participants in terms of sex, ethnicity/nationality, location, age, and other 
characteristics. However, optimal mechanisms and tools for achieving this inclusiveness are 
unclear. This field could benefit from understanding the experience of the HIV vaccine 
research field over the past several decades.107 Research opportunities in this realm include 
community-based research on how to ensure inclusiveness and representativeness in HIV 
cure studies and approaches to improve the likelihood of equitable implementation of and 
access to efficacious HIV cure strategies, especially in resource limited settings.
Health systems research
Modelling research could help researchers understand which individual cure strategy or 
group of strategies would be optimal for achieving population-level effects108. Both cost-
effectiveness (i.e., will the strategy be worth paying for?) and budgetary impact research 
(i.e., will the strategy be affordable?) will be important, especially in resource-limited 
settings109. Identifying who will pay for a cure and how prices will be established is also 
critical. Studies on how best to enhance public-private collaboration towards an HIV cure 
could alleviate some of the regulatory and logistical challenges associated with drug 
development.
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Global perspectives
The local context of HIV cure research will likely prove to be critical. For example, previous 
examples of ineffective HIV "cures" in Sub-Saharan Africa110 may influence how HIV-
infected individuals perceive HIV cure research moving forward. The cost of delivering a 
cure would likely be different in these resource-constrained contexts. Yet, to date, none of 
the existing literature has focused on low-income country contexts that have a higher burden 
of HIV and would potentially have the greatest to benefit from a cure.
CONCLUSION
The development of a safe, affordable and scalable strategy that results in complete 
eradication of HIV or sustained virus control in absence of therapy is a key priority of the 
IAS, funders, and the broader HIV community. Once considered aspirational, there are now 
a number of potential therapeutic strategies that could conceivably achieve this goal. The 
challenges, however, remain significant. A central premise of the IAS Global Scientific 
Strategy is that a multi-disciplinary, collaborative and sustained effort will be needed to 
overcome these challenges. The strategy outlined here highlight the priority areas for 
research and will hopefully guide a global strategic research effort and inspire new 
investigators to engage in the challenge.
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TEXT BOX 1
Defining cure in HIV disease
The definition of cure is important to clarify for researchers, clinicians, and people living 
with HIV. The optimal outcome would be the complete eradication within an individual 
of all replication-competent HIV. Such a sterilising cure will be challenging to achieve 
and will be impossible to prove with the current technologies111. A more feasible 
outcome will be the achievement of a long-term remission. Remission is likely a 
necessary precursor towards the development of an HIV cure, and is increasingly utilised 
in the field to indicate the goal of long-term undetectable viremia for an as-yet undefined 
period (likely of several years) in the absence of ART112. The concept of disease 
remission denotes improvement albeit with some uncertainty and is already well-
entrenched in medical settings113.
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TEXT BOX 2
Progress in HIV Cure Research 2012–2016
There have been a number of significant advances since the publication of the first 2012 
Global Scientific Strategy Towards an HIV Cure3. Sustained periods of aviremia in the 
absence of therapy was achieved in an aggressively treated infant, in at least two 
individuals who have received allogeneic stem cell transplant, and adults who received 
several years of ART that was initiated soon after infection (Figure 1)62,94,114,115. Non-
human primate and humanized mouse models of well-treated SIV/HIV disease have been 
validated and used to advance the scientific agenda63,116. Most HIV in blood was found 
to be replication-incompetent and most of the apparent replication-competent virus was 
found to be non-inducible ex vivo8. Early initiation of ART limits the establishment of 
the reservoir and prevents the generation of immune escape in latently infected 
cells63,117,118. New tools that can quantify the frequency of a cell that carries replication 
competent virus have been developed88,119, and some biomarkers have been shown to 
predict the time to viral rebound following a treatment interruption92,93,120,121. The 
central role of the T follicular helper cells and the B cell follicle in supporting SIV/HIV 
replication was established35. The central role of long-lived self-renewing memory CD4+ 
T cells as a reservoir during sustained ART (> 10 years) was established122, while the 
role of monocytes/macrophages as a stable reservoir during ART has been 
challenged36,123. Homeostatic proliferation induced by cytokines or HIV integration 
events as a mechanism of persistence was demonstrated25,39,40,124. Evidence was 
presented suggesting that HIV continues to replicate and evolve during the first 6 months 
of ART125 but not necessarily during long-term ART13. New latency reversing agents and 
combination approaches were identified in vitro21,126–128 and the capacity of more 
established LRAs to disrupt latency was demonstrated in a series of phase I/II clinical 
trials15–17,22,129. Novel vaccines were developed that contained and possibly cured SIV 
infection when administered before infection46, and the safety and potential efficacy of 
broadly neutralizing antibodies and bi-specific antibodies demonstrated47,51,52,54,130,131. 
The safety of gene therapy with CCR5 modification was found to be feasible and 
safe10,132.
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TEXT BOX 3
Methodology
This second edition of the Global Scientific Strategy: Towards an HIV Cure was 
developed under the auspices of the International AIDS Society (IAS) to revise and 
update the original strategy released in 2012. The strategy was discussed and developed 
by the International Scientific Working Group, a global team of leading stakeholders, 
including basic scientists, clinical physicians, social scientists, ethicists, and community 
leaders from around the world. The International Scientific Working Group was 
composed of seven multidisciplinary subgroups, including input from medical ethicists in 
each subgroup.
The Global Scientific Strategy (GSS) was discussed, developed and finalised at a series 
of in-person workshops and electronic discussions from autumn 2014 to February 2016. 
In addition to the discussions with the International Scientific Working Group, the GSS 
underwent broad dissemination for a peer-review process incorporating comments and 
edits from a broad range of stakeholders, in keeping with the values of the International 
AIDS Society. These research recommendations represent the culmination of hundreds of 
hours of online and in-person meetings with community leaders, pharmaceutical 
company representatives, funders and regulatory agency representatives, as well as HIV 
researchers from low-income, middle-income, and high-income country contexts. A 
number of non-HIV researchers were consulted on specific scientific issues.
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Figure 1. Cases of post-treatment control and resission
Viral rebound following cessation of ART usually occurs within 2–3 weeks. In some 
circumstances viral rebound has been significantly delayed in the setting of stem cell 
transplantation (Boston patients) or very early ART in an infant (Mississippi child). In some 
individuals, long term post treatment control (PTC) off ART has been achieved. In these 
PTC, ART was nearly always initiated in acute infection and virus is usually detected at low 
levels in plasma. Timothy Brown remains the only HIV-infected individual off ART with no 
virus detected in blood or tissue. He received a stem cell transplant from a donor who was 
CCR5D32 negative and remains off ART for over 7 years.
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Figure 2. Mechanisms that maintain HIV latency in resting CD4+ T-cells
There are multiple blocks to viral production in latently infected resting CD4+ T-cells 
including the site of integration (1), epigenetic silencing (2), lack of cellular transcription 
factors (3), incomplete elongation of transcripts (4), nuclear retention of transcripts (5) and 
micro RNAs limiting translation of viral proteins (6). TCR = T cell receptor; TF = 
transcription factors; co-Act = co-activators; MS = multiply spliced; US = unspliced; 
miRNA = microRNA.
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Figure 3. Using targeted nucleases against HIV
Targeted nucleases, such as zinc finger nucleases and CRISPR/Cas9, provide more precise 
methods of gene therapy. They create site-specific DNA breaks, whose subsequent repair by 
the non-homologous end joining (NHEJ) pathway can be exploited to disrupt a gene, such as 
CCR5, or even an integrated HIV genome. Alternatively, repair can occur through 
homologous recombination, and a co-introduced DNA homology template can be designed 
to create small mutations in host genes, or direct the site-specific insertion of an anti-HIV 
gene.
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Figure 4. Assays used to quantify HIV persistence on ART
The frequency of cells that produce infectious virus is only a subset of cells that are infected 
with intact (highlighted in a red line) and defective genomes (total pool of infected cells). 
US = unspliced; MS = multiply spliced; QVOA = quantitative viral outgrowth assay; MVOA 
= murine viral outgrowth assay
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